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doi:10.1Objective: Approximately 10% of patients undergoing cardiac surgery have perioperative myocardial injury.
A recent genome-wide association study identified an association between myocardial infarction in nonsurgi-
cal populations and common genetic variants on chromosome 9p21. We hypothesized that these variants are
also associated with perioperative myocardial injury after isolated primary coronary artery bypass graft
surgery.
Methods: In a prospective observational study of 846 Caucasian patients undergoing primary coronary bypass
surgery at 2 US centers, we genotyped 61 linkage-disequilibrium tagging single nucleotide polymorphisms,
encompassing 436 kbp of the 9p21 region. A multivariable logistic model was used to adjust for previously iden-
tified clinical covariates of perioperative myocardial injury. Perioperative myocardial injury was defined as
a postoperative day 1 cardiac troponin I in the top 10th percentile (>9.13 mg/L) of the cohort. Multiple testing
of single nucleotide polymorphisms was corrected for with family-wise errors.
Results: Prior myocardial infarction and longer cardiopulmonary bypass time were significant independent
predictors of perioperative myocardial injury. Levels of postoperative cardiac troponin I were incrementally in-
creased for each additional copy of the risk alleles of 3 single nucleotide polymorphisms: rs10116277, rs6475606,
and rs2383207. Adjusted additive odds ratios ranged between 1.64 and 1.79 (asymptotic P value between 3.73
103 and 6 3 104) and remained significantly associated with perioperative myocardial injury even after
accounting for clinical covariates including severity of coronary disease, and multiple comparisons.
Conclusions: We have now demonstrated that common genetic variants in the same 9p21 locus, previously known
to be associated with myocardial infarction in nonsurgical populations, are also associated with perioperative myo-
cardial injury after coronary artery bypass grafting. Further investigation is warranted to elucidate functional
mechanisms. (J Thorac Cardiovasc Surg 2010;139:483-88)Supplemental material is available online.
Multiple epidemiologic studies have documented a signifi-
cant heritability for coronary artery disease (CAD) and
myocardial infarction.1 Using an unbiased genome-wide
approach, recent studies identified an association between
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Mwith common genetic variants on chromosome 9p21 in
nonsurgical populations.2-4 Although the responsible
molecular genetic determinants remain largely unidentified,
these variants are adjacent to genes for the cyclin-dependent
kinases CDKN2A/B, which play a critical role in regulating
cell aging, cell proliferation, and apoptosis,5-8 as well as
ANRIL, a large antisense noncoding RNA gene, shown to
be expressed in cell types integral to atherosclerosis.9-11
Perioperative myocardial injury (PMI), which afflicts
nearly 1 million people annually during or after noncardiac
surgery worldwide,12 has conventionally been associated
with transient myocardial ischemia and reperfusion owing
to aortic occlusion, cardiotomy, and an obligatory acute
inflammatory response associated with cardiopulmonary
bypass (CPB). Although a few limited studies have impli-
cated a heritable risk of PMI,13,14 variants in the 9p21 region
have not yet been examined for an association with this
adverse perioperative outcome. Therefore, we hypothesized
that variants in the 9p21 region are also independently
associated with PMI after isolated primary coronary artery
bypass graft (CABG) surgery with CPB.METHODS
Two institutions (Brigham and Women’s Hospital and Texas Heart Insti-
tute, recruited patients within a single study structure known as the CABGrdiovascular Surgery c Volume 139, Number 2 483
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M48Abbreviations and Acronyms4CABG ¼ cThe Joronary artery bypass graftCAD ¼ coronary artery disease
CPB ¼ cardiopulmonary bypass
cTNI ¼ cardiac troponin I
PMI ¼ perioperative myocardial injury
POD ¼ postoperative day
SNP ¼ single nucleotide polymorphismGenomics Program (http://clinicaltrials.gov/show/NCT00281164). After
August 2001, we prospectively enrolled patients aged 20 to 90 years under-
going nonemergency primary CABG surgery with CPB, without other con-
current surgery. Patients with a preoperative hematocrit value of less than
25% or transfusion of leukocyte-rich blood products within 30 days before
the operation were not enrolled. To avoid potential population stratification,
we restricted analysis to subjects who self-reported 4 Caucasian grandparen-
tal ancestry. Study protocols were approved by the respective institutional
review boards, and participants were enrolled after providing informed writ-
ten consent. The funding agencies had no involvement in study design, data
interpretation, or data analysis.
Data Collection
At each site, we recorded patient demographics, perioperative risk fac-
tors, medications, and postoperative outcomes using study-specific case
report forms. Blood samples were drawn before induction of general anes-
thesia, after administration of post-CPB protamine, and on the mornings of
postoperative days (PODs) 1 to 5. Serum and plasma were stored in vapor-
phase liquid nitrogen until analysis for cardiac troponin I (cTnI), B-type
natriuretic peptide, and creatine kinase MB fraction on a sandwich immuno-
assay on a Triage platform using monoclonal and polyclonal antibodies (Bi-
osite Inc, San Diego, Calif) at a single core facility. Myocardial injury was
defined as POD 1 cTnI in the top 10th percentile (>9.13 mg/L).
Genotyping
DNA was extracted from white blood cells by standard procedures.
Linkage-disequilibrium tagging single-nucleotide polymorphisms (SNPs)
between chromosome 9 positions 21,930,588-22,366,970 (NCBI Genome
Build 36 assembly) encompassing the originally identified 9p21 region
with minor allele frequencies of 5% or greater in the HapMap Caucasian
cohort were identified using Tagger.15 Overall, 61 tagging SNPs that
described 70.8% of the variation with a mean r2 of 0.8 in the 394 HapMap-
identified SNPs were genotyped (Supplemental Table 1) using the
Golden Gate assay with an Illumina Bead Station 500 G system (Illumina,
San Diego, Calif), in accordance with the manufacturer’s standard
recommendations.. The raw data were analyzed with the clustering
algorithm of the Illumina BeadStudio software and individual examination
of all intensity plots, with manual curation of genotype calls. SNPs
with genotyping call rate less than 95%, with significant deviation
from Hardy–Weinberg equilibrium (P< .001 in controls) and nonrandom
missingness (P< .05) between cases and controls, were excluded from
subsequent analysis.
Statistical Analysis
Categorical and continuous demographic characteristics were compared
between groups with likelihood ratio c2 and Wilcoxon rank sum tests,
respectively. A multivariable logistic model was used to derive periopera-
tive and demographic variables associated with PMI, including severity
of CAD. Factors previously associated with PMI after cardiac surgery in
prior studies, including acute coronary syndrome, were forced into the logis-ournal of Thoracic and Cardiovascular Surgtic regression model along with clinically relevant variables using stepwise
selection. PLINK (version 1.04) and SAS (version 9.1.3; SAS Institute, Inc,
Cary, NC) were used for genetic association analysis. Hardy–Weinberg
equilibrium was evaluated by an exact test. After application of genotype
quality control criteria, univariate analyses were carried out for each SNP
to test the null hypothesis of no association between marker polymorphism
and PMI, based on log-additive genetic models. Adjusted odds ratios of
every SNP for PMI were estimated by the aforementioned multivariable
logistic regression model. To correct for multiple testing, we report tests
of significance as family-wise empirical P values based on permuting
case–control status.RESULTS
Between August 2001 and August 2006, 877 Caucasian
patients were genotyped as described in the Methods
section. Thirty-one patients had genotyping rates of less
than 90% or were missing biomarkers and were excluded.
Patient characteristics stratified by PMI status after
primary CABG surgery are shown in Table 1. Eighty-five
patients (top 10th percentile) had a POD 1 cTnI level greater
than 9.13 mg/L and therefore were classified as having PMI.
Patients who had a history of myocardial infarction, lower
preoperative left ventricular ejection fraction, longer CPB
duration or aortic crossclamp time, or were not receiving
preoperative angiotensin-converting enzyme inhibitors
were more likely to have PMI. Similarly, elevated preoper-
ative cTnI and creatine kinase MB, but not preoperative
B-type natriuretic peptide, were associated with a higher
risk of PMI. The degree of coronary artery stenosis by
angiography or the number of vessels grafted intraopera-
tively was not significantly different between patients who
had PMI and those who did not. Patients with PMI were
hospitalized for 1 additional day but did not have significant
differences in all-cause mortality. Multivariable logistic
model identified recent myocardial infarction and longer
duration of CPB time as significant independent predictors
of PMI (Table 2).
All 61 SNPs passed quality control by genotyping call
rate, Hardy–Weinberg equilibrium, and nonrandom miss-
ingness. One SNP had an observed minor allele frequency
of 1% and was excluded from further analysis, leaving a total
of 60 remaining SNPs that were included in the analysis
(Table E1). Levels of postoperative cTnI were incrementally
increased for each additional copy of the minor allele (ie, the
risk allele in our cohort) of rs10116277 (Figure 1),
rs6475606, and rs2383207. These three SNPs within the
coding region of ANRIL were also significantly associated
with PMI, even after accounting for clinical covariates and
multiple comparisons using an additive genetic model (Ta-
ble 3). Careful inspection of model fit statistics, based on
commonly used statistical criteria (likelihood ratio, Nagel-
kerke R2, Akaike information criterion, and Schwarz–
Bayesian information criterion), revealed very substantial
incremental improvement of adding these 9p21 variants
into the clinical predictive multivariable model of PMI.ery c February 2010
TABLE 1. Demographics and clinical characteristics
cTnI<9.13
mg/L (N ¼ 761)
cTnI  9.13
mg/L (N ¼ 85)
P
value
Demographics
Gender (N,% male) 628 (83) 67 (79) .374
Institution (N,%) 615 (81) 70 (82) .884
Age (y) 64 (57–72) 65 (59–74) .291
BMI (kg/m2) 28.5 (25.8–31.9) 28.3 (25.0–32.7) .972
Medical history
LVEF preop (%) 55 (45–60) 50 (45–60) .014
Diabetes
(insulin-dependent or
non–insulin dependent;%)
203 (27) 16 (19) .150
Pulmonary disease
(COPD, asthma;%)
32 (4) 3 (4) .767
Creatinine (mg/dL) 1 (0.9–1.2) 1.1 (0.9–1.3) .401
Hematocrit (%) 40 (34–44) 40 (37–43) .520
Hypertension (%) 570 (75) 60 (71) .360
Hypercholesterolemia (%) 581 (76) 62 (74) .591
Coronary stenosis (>50%) regions
2 165 (22) 14 (16)
3 388 (51) 49 (58)
 4 208 (27) 22 (26) .417
Previous myocardial
infarction
309 (41) 46 (54) .021
Myocardial infarction
within prior 2 wk (%)
119 (16) 26 (31) .001
Medications—preoperative (N,%)
ACE inhibitor 30 (35) 362 (48) .039
b-blocker 587 (77) 66 (78) .915
Caþþ antagonist 103 (14) 8 (9) .396
Aspirin 568 (75) 60 (71) .434
HMG CoA reductase inhibitor 583 (77) 60 (71) .229
Biomarkers–preoperative
BNP (mg/L) 18 (5–56) 26 (6–72) .112
CKMB (mg/L) 0.5 (0.2–1.2) 0.9 (0.3–3.0) <.001
cTnI (mg/L) 0.01 (0–0.03) 0.03 (0–0.9) <.001
Surgery
No. of grafts (N,%)
2 119 (16) 13 (15)
3 356 (47) 41 (48)
4 286 (38) 31 (36) .968
CPB duration (min) 94 (66–117) 108 (85–138) <.001
Aortic crossclamp
duration (min)
71 (41–90) 82 (61–107) <.001
Postoperative data
HLOS (d) 7 (6–9) 8 (6–10) .001
Mortality (%, N) up to 5 y 52 (7) 10 (12) .120
cTnI, Cardiac troponin I; BMI, body mass index; LVEF, left ventricular ejection
fraction; COPD, chronic obstructive pulmonary disease; ACE, angiotensin-converting
enzyme; HMG CoA, 3-hydroxy-3-methyl-glutaryl coenzyme A reductase; BNP,
B-type natriuretic peptide; CKMB, creatinine kinase MB fraction; CPB, cardiopulmo-
nary bypass; HLOS, hospital length of stay.
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MSignificant pairwise linkage disequilibrium was present in
the region that precludes identification of a single associated
variant (Figure 2). The SNP rs10811661, previously associ-The Journal of Thoracic and Caated with type 2 diabetes,16 had no association with PMI in
our cohort and is also not in linkage disequilibrium with
SNPs associated with PMI (Figure 2).
DISCUSSION
We have shown that variants on 9p21 previously
associated with cardiovascular disease, CAD or myocardial
infarction in ambulatory nonsurgical populations, are also
associated with PMI after CAGB surgery with CPB.
Furthermore, we confirmed that this association is indepen-
dent of type 2 diabetes, and with the SNP rs10811661,
previously associated with type 2 diabetes.16 Additionally,
although variants within the 9p21 chromosonal locus have
been associated with CAD in nonsurgical patients, the asso-
ciation we observed between 9p21 SNPs and PMI in our co-
hort was independent of CAD severity assessed by coronary
angiogram. Similarly, while the SNPs associated with CAD
and MI in nonsurgical patients are the same as for PMI in our
cohort with severe CAD, the specific risk alleles in each pop-
ulation are different. Nonetheless, to our knowledge, this is
the first report demonstrating a unique and novel association
between 9p21 variants and any adverse perioperative out-
come.
Despite considerable efforts by geneticists, the underlying
mechanisms of the association of 9p21 with cardiovascular
disease, CAD and myocardial infarction, have not been
elucidated. The 9p21 region encompassing the identified
SNPs is flanked by two recombination hotspots and is
adjacent to the cyclin-dependent kinases CDKN2A and
CDKN2B, which have important roles in cell cycle regula-
tion.11 Through their role in transforming growth factor
b–induced growth inhibition, the cyclin-dependent kinases
have been implicated in the pathogenesis of atherosclero-
sis,17 although their role in acute events such as myocardial
infarction has yet to be elucidated. A recent study found that
probands with the 9p21 risk allele had decreased expression
of the CDKN2A/2B locus in peripheral blood leukocytes18
and that inactivation of CDKN2B and/or CDKN2A allows
cells to escape cell cycle arrest or become senescent.11
Senescent cells are resistant to programmed cell death, lead-
ing to accumulation of these cells in injured tissue with
substantial effects on healthy neighboring tissue.19 Hypo-
thetically, ischemic injury may unmask and accelerate the
effects of the 9p21 variants with at-risk patients more
susceptible to senescent cell accumulation. Also of interest,
the associated SNPs lie within ANRIL, a large antisense
noncoding RNA gene, considered to be operating in the tran-
scriptional control repertoire of the cell and expressed in
tissues and cell types affected by atherosclerosis.10 Experi-
mental evidence suggests possible coordinated transcrip-
tional regulation of ANRIL mediated by cyclin-dependent
kinase.10
In addition to being a risk factor for CAD and having an
association with myocardial infarction, variation in 9p21rdiovascular Surgery c Volume 139, Number 2 485
TABLE 2. Multivariable clinical predictor model of perioperative
myocardial injury
Predictor Odds ratio (95% CI) P value
Age (decile) 1.11 (0.88–1.39) .378
Gender (male) 1.25 (0.69–2.28) .457
Institution 0.66 (0.86–3.2) .131
Preoperative HMG CoA reductase
inhibitor use
0.73 (0.44–1.22) .232
Myocardial infarction within
previous 2 weeks
2.29 (1.37–3.84) .002
Coronary stenosis (>50%) regions
 2 1
3 1.14 (0.60–2.18)
 4 0.97 (0.47–2.01) .80
CPB time 1.14 (1.08–1.21) <.0001
Preoperative creatinine 1.56 (0.16–15.5) .70
Important clinical and demographic variables from Table 1 selected by stepwise
regression and entered into multivariable model. CI, Confidence interval; HMG
CoA, 3-hydroxy-3-methyl-glutaryl coenzyme A; CPB, cardiopulmonary bypass, in
increments of 10 mimutes.
FIGURE 1. Cardiac troponin I level for 9p21 risk allele. The SNP
rs10116277 plotted against cardiac troponin I values on the 7 perioperative
time points. The bars on an individual day represent the copies of the risk
allele; the first bar represents two copies, the second bar one copy, and
the third bar no copy of the risk allele. Each bar represents median with
interquartile range and outliers are shown by the dotted lines. *P< .01.
cTnI, Cardiac troponin I; Pre, preoperatively; Post, immediately after
protamine.
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Mhas also been associated with carotid atherosclerosis,
progression of atherosclerosis,20 and abdominal aortic aneu-
rysm.21,22 Surprisingly, 9p21 variants are also associated
with intracranial aneurysms,22 a disease not mediated by ath-
erosclerosis. However, the role of variants in 9p21 does not
appear to be mediated through vascular reactivity.23 This
lack of association with vascular reactivity, along with the
relation of the 9p21 locus to aneurysms, suggests a mecha-
nism more complex than simply promoting atherosclerotic
plaque development.
The etiology of PMI occurring during cardiac surgery is
markedly different from myocardial infarction occurring in
ambulatory populations. Nonsurgical myocardial infarction
is predominantly associated with prolonged stress-induced
myocardial ischemia (ie, non–ST-segment elevation
myocardial infarction) or coronary plaque disruption (ie,
ST-segment elevation myocardial infarction).24-26 By
contrast, CABG surgery with CPB requires aortic cross-TABLE 3. Selected 9p21 SNPs associated with PMI-based logistic regressi
Minor allele
frequency
SNP
Chr 9
position
Allele
(minor/major) Cases Controls
Odds ratio
(95% CI)
rs10116277 22,071,397 G/T 0.53 0.40 1.79 (1.29–2.51
rs6475606 22,071,850 C/T 0.53 0.40 1.79 (1.28–2.50
rs1333040 22,073,404 C/T 0.46 0.33 1.66 (1.20–2.28
rs2383206 22,105,026 A/G 0.50 0.38 1.67 (1.20–2.32
rs2383207 22,105,959 A/G 0.50 0.37 1.71 (1.23–2.38
rs10757278 22,114,477 A/G 0.54 0.42 1.70 (1.22–2.38
Six most significant SNPs by asymptotic P value selected. For entire SNP list, see Supple
injury; Chr, chromosome; CI, confidence interval; FWER, family-wise error rate; MI, myo
multivariable model in Table 2. yAsymptotic P value covariate adjusted. zFamily-wise em
486 The Journal of Thoracic and Cardiovascular Surgclamping and the use of cardioplegic solutions with
obligate ischemia and profound coagulation and inflamma-
tory responses. Thus it is perhaps surprising that the
genetic evidence of common 9p21 association with both
myocardial infarction in nonsurgical populations and
PMI supports common molecular mechanisms in both
phenotypes.
Similar to the previously published genome-wide associ-
ation studies in the ambulatory population, the most likely
mode of inheritance in our population is an additive model.
In contrast, the odds ratios per copy of the risk allele between
1.66 and 1.79 that we observed were significantly higher
than the average of 1.3 in associations with cardiovascular
disease in the genome-wide association studies in Cauca-
sians.6 The variability in risk may be attributed to interaction
with environmental factors and the examination of a pro-
voked phenotype; all patients, cases and controls, had
CAD severe enough to warrant CABG surgery. Comparedon model
Covariate-adjusted additive
genetic model*
Prior nonsurgical MI
studiesAsymptotic P valuey
FWER permuted
P valuez
) .001 .019 (7)
) .001 .020
) .002 .054 (7)
) .002 .061 (2)
) .001 .040 (7)
) .001 .052 (7)
ment Table 1. SNP, Single nucleotide polymorphism; PMI, perioperative myocardial
cardial infarction. *The cohort-specific clinical model consists of predictors from the
pirical P value is used to adjust for multiple comparisons.
ery c February 2010
FIGURE 2. Linkage-disequilibrium (LD) plot of 9p21 region. The upper panel shows negative log10 P values for the association of the individual single
nucleotide polymorphism (SNPs) at their physical location with perioperative myocardial injury (PMI), after adjustment in multivariable regression model.
The lower panel summarizes the LD structure in the HapMap database (CEU European ancestry). Regions of LD are shaded in gray (moderate LD) or black
(strong LD). Predicted haplotype blocks are framed by triangles. The physical location of the genes CDKN2A, CDKN2B, and ANRIL are shown in the
HapMap info tack above the SNPs. The type 2 diabetes locus is seen on the far right side of the LD plot, with a nonsignificant association with PMI.
CDKN, Cyclin-dependent kinase; ANRIL, antisense noncoding RNA gene; T2D, type 2 diabetes.
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Mwith the nonsurgical setting, the incidence of myocardial
injury in our population is extremely high.
Although genetic variation in the 9p21 locus is associated
with incident cardiovascular disease across many different
populations and has a high frequency of the risk allele
with a substantial increase in the probability of developing
disease with each allele, the utility of screening for this poly-
morphism to improve risk prediction remains unclear. We
observed very substantial incremental improvement of add-
ing 9p21 variants into clinical predictive models of PMI.
Similarly, in the Caucasian population of the Atherosclerosis
Risk in Communities study (n ¼ 10,004), adding 9p21 var-
iation to traditional risk factors improved CAD risk predic-
tion and reclassification, particularly in higher risk
categories. Conversely, in the Women’s Genome Health
Study (n ¼ 22,129), genetic variation in 9p21 did not
improve discrimination or classification of predicted risk.27
Therefore, further investigation is warranted before the
genetic variation in 9p21 can be routinely incorporated
into perioperative risk prediction models.
Limitations
We have not yet replicated our findings in a separate
cardiac surgical cohort. However, the 9p21 region is the
most replicated locus for CAD and myocardial infarctionThe Journal of Thoracic and Cato date across multiple populations. Furthermore, despite
examining the entire region, we have observed consistent
and strong effect sizes at the same SNPs previously
described.
Population stratification, a limitation to all genetic associ-
ation studies, was addressed by including patients in the
analysis who self-reported 4 generations of Caucasian
grandparental ancestry. In addition, we tested genomic
controls and tested for differences between Northern and
Southern Europeans. Accordingly, we believe that this
association is not driven by cryptic heterogeneity.
In a study of this magnitude across two centers and many
practitioners, differences in treatment will exist. Institutional
differences are unlikely to confound the observed associa-
tion between 9p21 variants and PMI for these reasons: (1)
personnel and patients were blinded to genotype and perio-
perative cTnI measurements performed as part of the study;
(2) within this cohort, we did not observe any association
between genotype and risk factors for PMI; and (3) within
this cohort, it is highly unlikely that concomitant therapies
were associated with genotype, with the possible exception
of gender, which was included in all models.
Our analysis was limited to Caucasians and therefore
these results are not generalizable to other ethnic groups
with variable allele frequencies.rdiovascular Surgery c Volume 139, Number 2 487
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MCONCLUSION
We have identified common genetic variants in 9p21
within or adjacent to genes CDKN2A/B and ANRIL,
involved in cell-cycle regulation and atherosclerosis, which
are significantly and independently associated with PMI in
patients undergoing CABG with CPB. Further investigation
is warranted to elucidate the mechanisms by which the
variants exert their effects on the development of PMI.
We acknowledge the outstanding contributory efforts of the
CABG Genomics research staff: James Gosnell, RN; Kujtim
Bodinaku, MD; Jai Madan, MD, MPH; Svetlana Gorbatov,
MPH; James Chen, RN; and Isabella Candelaria. We thank all
study subjects who participated in the CABG Genomics Program
and surgeons who identified their patients.References
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TABLE E1. Sixty 9p21 SNPs considered for association with PMI based on logistic regression model
Minor allele frequency
Covariate-adjusted additive
genetic model*
SNP Chr 9 position
Allele
(minor/major) Cases Controls Odds ratio (95% CI)
Asymptotic
P valuey
FWER permuted
P valuez
rs10965189 21930588 A/C 0.03 0.04 0.76 (0.30–1.93) .559 1.000
rs10965197 21938666 T/C 0.45 0.42 1.11 (0.79–1.55) .540 1.000
rs2518722 21942926 T/C 0.27 0.31 0.82 (0.56–1.20) .310 1.000
rs12335941 21945669 G/A 0.37 0.42 0.82 (0.58–1.16) .266 1.000
rs2027938 21946078 A/G 0.25 0.28 0.89 (0.61–1.30) .535 1.000
rs9657608 21946230 T/C 0.09 0.10 0.98 (0.56–1.72) .952 1.000
rs7041637 21951866 A/C 0.31 0.30 1.02 (0.71–1.47) .916 1.000
rs3731257 21956221 T/C 0.29 0.26 1.11 (0.77–1.61) .569 1.000
rs11515 21958199 G/C 0.15 0.17 0.86 (0.55–1.33) .498 1.000
rs2811708 21963422 T/G 0.26 0.31 0.79 (0.54–1.15) .213 .996
rs3731239 21964218 C/T 0.35 0.31 1.16 (0.81–1.64) .416 1.000
rs2811709 21970151 A/G 0.12 0.13 0.95 (0.59–1.54) .838 1.000
rs4074785 21971583 A/G 0.10 0.09 1.13 (0.66–1.93) .657 1.000
rs3731222 21973914 G/A 0.13 0.16 0.81 (0.50–1.32) .400 1.000
rs3731211 21976847 A/T 0.26 0.33 0.72 (0.50–1.06) .097 .907
rs10757262 21977874 T/A 0.14 0.16 0.83 (0.52–1.30) .409 1.000
rs3218020 21987872 T/C 0.38 0.41 0.81 (0.58–1.13) .217 .997
rs3218009 21988757 C/G 0.14 0.08 1.87 (1.15–3.04) .011 .261
rs3217992 21993223 A/G 0.40 0.45 0.76 (0.54–1.07) .111 .936
rs1063192 21993367 C/T 0.41 0.34 1.43 (1.01–2.01) .045 .670
rs2069418 21999698 C/G 0.43 0.36 1.38 (0.98–1.94) .063 .787
rs495490 22000412 C/T 0.10 0.10 1.08 (0.63–1.86) .790 1.000
rs573687 22001642 T/C 0.35 0.29 1.38 (0.96–1.96) .079 .855
rs13298881 22002051 C/T 0.13 0.14 0.87 (0.54–1.41) .581 1.000
rs545226 22002422 C/T 0.43 0.46 0.86 (0.61–1.19) .357 1.000
rs643319 22007836 T/G 0.45 0.41 1.25 (0.90–1.76) .188 .992
rs523096 22009129 C/T 0.43 0.35 1.43 (1.02–2.00) .038 .604
rs518394 22009673 G/C 0.43 0.36 1.46 (1.03–2.05) .031 .539
rs564398 22019547 G/A 0.40 0.32 1.52 (1.07–2.15) .020 .398
rs17694493 22031998 G/C 0.14 0.14 0.94 (0.59–1.51) .801 1.000
rs1412830 22033612 A/G 0.36 0.29 1.48 (1.05–2.09) .027 .498
rs1011970 22052134 T/G 0.15 0.18 0.85 (0.55–1.32) .477 1.000
rs10811650 22057593 A/G 0.55 0.49 1.37 (0.98–1.90) .064 .792
rs10757270 22062719 A/G 0.55 0.48 1.36 (0.98–1.89) .063 .787
rs1412832 22067543 C/T 0.31 0.22 1.58 (1.10–2.28) .013 .290
rs10116277 22071397 G/T 0.53 0.40 1.79 (1.29–2.51) .001 .019
rs6475606 22071850 C/T 0.53 0.40 1.79 (1.28–2.50) .001 .020
rs1547705 22072375 C/A 0.13 0.16 0.77 (0.48–1.23) .276 1.000
rs1333040 22073404 C/T 0.46 0.33 1.66 (1.20–2.28) .002 .054
rs10738607 22078094 A/G 0.53 0.41 1.65 (1.19–2.30) .003 .077
rs10757272 22078260 C/T 0.52 0.41 1.59 (1.14–2.21) .006 .157
rs4977574 22088574 A/G 0.52 0.40 1.63 (1.17–2.27) .004 .103
rs10125231 22092128 A/G 0.02 0.04 0.53 (0.16–1.75) .297 1.000
rs1333042 22093813 A/G 0.50 0.38 1.65 (1.19–2.30) .003 .079
rs2383206 22105026 A/G 0.50 0.38 1.67 (1.20–2.32) .002 .061
rs2383207 22105959 A/G 0.50 0.37 1.71 (1.23–2.38) .002 .040
rs1333045 22109195 T/C 0.50 0.39 1.63 (1.17–2.28) .004 .113
rs10757278 22114477 A/G 0.54 0.42 1.70 (1.22–2.38) .002 .052
rs10757279 22114630 A/G 0.54 0.42 1.65 (1.18–2.32) .004 .098
rs1333048 22115347 A/C 0.51 0.40 1.64 (1.18–2.30) .004 .098
rs1333049 22115503 C/G 0.54 0.42 1.67 (1.20–2.33) .003 .066
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TABLE E1. Continued
Minor allele frequency
Covariate-adjusted additive
genetic model*
SNP Chr 9 position
Allele
(minor/major) Cases Controls Odds ratio (95% CI)
Asymptotic
P valuey
FWER permuted
P valuez
rs2891169 22121825 G/A 0.39 0.40 0.92 (0.66–1.28) .626 1.000
rs2383208 22122076 G/A 0.14 0.19 0.66 (0.41–1.06) .084 .870
rs10811661 22124094 C/T 0.13 0.18 0.68 (0.42–1.10) .117 .946
rs10757283 22124172 T/C 0.43 0.44 0.92 (0.66–1.28) .603 1.000
rs6475610 22131894 T/C 0.49 0.49 0.99 (0.72–1.36) .947 1.000
rs10757289 22150454 C/G 0.46 0.41 1.23 (0.89–1.71) .214 .997
rs1679013 22196987 T/C 0.51 0.50 1.08 (0.78–1.50) .659 1.000
rs10113901 22364032 C/T 0.49 0.49 0.97 (0.70–1.34) .837 1.000
rs7046709 22366970 G/A 0.34 0.34 1.00 (0.71–1.41) .987 1.000
Six most significant SNPs by asymptotic P value selected for Table 1 are shaded in gray. SNP, Single nucleotide polymorphism; PMI, perioperative myocardial injury; Chr,
chromosome; CI, confidence interval; FWER, family-wise error rate. *The cohort-specific clinical model consists of predictors from the multivariable model in Table 2.
yAsymptotic P value covariate adjusted. zFamily-wise empirical P value is used to adjust for multiple comparisons.
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